Literature DB >> 17902116

Pharmacological issues in the management of people with mental illness and problems with alcohol and illicit drug misuse.

Trudi Hilton1.   

Abstract

BACKGROUND: While there is plentiful information on the pharmacological management of detoxification from alcohol and on withdrawal from or maintenance of opiates for people with a principal problem of substance misuse or dependency, the pharmacological management of substance misusers presenting with a mental illness can be more complicated. Mental health and substance misuse services tend to be separate, but there is now a drive to increase effective overlap between them by equipping mental health clinicians with the skills and confidence to manage substance misuse disorders in conjunction with major mental illness. AIMS: This paper aims to highlight, for a multi-professional readership, some of the prescribing options and precautions to consider when psychotropic medicines are prescribed for treatment of a mental illness in someone who may continue to use illicit substances or alcohol. It also considers interactions with the completely licit substances, nicotine and caffeine. With recent legislation prohibiting smoking in public places people are likely to reduce or stop smoking, which can have a substantial effect on the levels of medication in their blood. Copyright (c) 2007 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17902116     DOI: 10.1002/cbm.669

Source DB:  PubMed          Journal:  Crim Behav Ment Health        ISSN: 0957-9664


  2 in total

Review 1.  The impact of lifestyle factors on the physical health of people with a mental illness: a brief review.

Authors:  Susanne Stanley; Jonathan Laugharne
Journal:  Int J Behav Med       Date:  2014-04

2.  How High? Trends in Cannabis Use Prior to First Admission to Inpatient Psychiatry in Ontario, Canada, between 2007 and 2017.

Authors:  Taylor McGuckin; Mark A Ferro; David Hammond; Shannon Stewart; Bridget Maloney-Hall; Nawaf Madi; Amy Porath; Christopher M Perlman
Journal:  Can J Psychiatry       Date:  2020-12-31       Impact factor: 4.356

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.